Tower Research Capital (TRC)’s Context Therapeutics CNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.66K Sell
25,495
-3,836
-13% -$1.89K ﹤0.01% 4456
2026
Q2
$16.2K Buy
29,331
+28,099
+2,281% +$57K ﹤0.01% 3724
2026
Q1
$3.23K Sell
1,232
-8,379
-87% -$19.6K ﹤0.01% 4350
2025
Q4
$14.1K Buy
+9,611
New +$11.2K ﹤0.01% 3367
2025
Q3
– Sell
-7,414
Closed -$4.86K – 5265
2025
Q2
$4.86K Sell
7,414
-5,890
-44% -$4.24K ﹤0.01% 4254
2025
Q1
$8.14K Buy
13,304
+12,370
+1,324% +$10.8K ﹤0.01% 3915
2024
Q4
$981 Sell
934
-6,221
-87% -$10.8K ﹤0.01% 5122
2024
Q3
$14K Buy
+7,155
New +$15.9K ﹤0.01% 3482
2024
Q2
– Sell
-6,357
Closed -$8.77K – 5720
2024
Q1
$8.77K Sell
6,357
-298
-4% -$335 ﹤0.01% 3966
2023
Q4
$7.52K Sell
6,655
-2,308
-26% -$2.48K ﹤0.01% 4608
2023
Q3
$13.5K Buy
8,963
+3,026
+51% +$3.42K ﹤0.01% 3778
2023
Q2
$9.5K Sell
5,937
-2,906
-33% -$2.47K ﹤0.01% 4271
2023
Q1
$5K Sell
8,843
-14
-0.2% -$11 ﹤0.01% 4943
2022
Q4
$6K Buy
8,857
+1,558
+21% +$1.68K ﹤0.01% 4696
2022
Q3
$8K Buy
7,299
+4,331
+146% +$7.8K ﹤0.01% 4767
2022
Q2
$6K Buy
2,968
+2,935
+8,894% +$5.5K ﹤0.01% 4902
2022
Q1
$0 Sell
33
-2,021
-98% -$4.25K ﹤0.01% 6134
2021
Q4
$6K Buy
+2,054
New +$10.2K ﹤0.01% 5013

Other funds holding CNTX

Tower Research Capital (TRC)'s CNTX Position: Q3 2026 in Review

Tower Research Capital (TRC) reduced its Context Therapeutics (CNTX) stake by 13% in Q3 2026, selling an estimated $1.89K and leaving 25,495 shares worth $7.66K. The position accounts for ﹤0.01% of the portfolio, ranked #4456.

Tower Research Capital (TRC) first reported a position in CNTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $16.2K in Q2 2026. 87 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

  • Tower Research Capital (TRC) held 25,495 shares of Context Therapeutics worth $7.66K as of Q3 2026.
  • Tower Research Capital (TRC) sold 3,836 Context Therapeutics shares in Q3 2026, an estimated $1.89K.
  • Context Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4456 holding.
  • Tower Research Capital (TRC) first reported a position in Context Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Context Therapeutics position peaked at $16.2K in Q2 2026.
  • 87 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.